HER2阳性T1N0乳腺浸润性导管癌患者的复发风险预后模型

• Format: Patent
• Language: Chinese
• Published: 05.12.2023
• Subjects: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATIONTECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING ORPROCESSING OF MEDICAL OR HEALTHCARE DATA; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS; PHYSICS

本发明公开了一种预预测受试者即HER2阳性T1N0乳腺浸润性导管癌患者是否预后不佳的方法和装置，所述方法包括计算所述受试者的总得分＝年龄得分+分期得分+ER/PR状态得分+Ki-67表达得分，如果总得分小于截断值，表明所述受试者预后不佳，如果总得分大于截断值，则预后良好，其中所述截断值为40.0-50.0分，优选为42.7分。 A method and device for predicting whether a subject, i.e., an HER2-positive T1N0 breast invasive ductal carcinoma patient, has a poor prognosis. The method comprises calculating the total score of the subject, which is equal to the sum of the age score, the staging score, the ER/PR state score, and the Ki-67 expression score; if the total score is less than a truncation value, indicating that the subject has a poor prognosis; and if the total score is greater than the truncation value, indicating that the prognosis is good, wherein the truncation value ranges from 40.0 to 50.0, preferably 42.7.